Figure 1
Figure 2
Figure 3
AI-based PCAT - FAI Score
| Parameters | Whole study sample (n = 172) | Group 1 (COVID-19) (n = 80) | Group 2 (non-COVID-19) (n = 92) | P-value * |
|---|---|---|---|---|
| FAI HU LAD, mean ± SD | −76.08 ± 7.66 | −75.07 ± 7.59 | −76.46 ± 7.74 | NS |
| FAI HU LCX, mean ± SD | −71.32 ± 7.50 | −71.44 ± 7.88 | −71.21 ± 7.16 | NS |
| FAI HU RCA, mean ± SD | −73.11 ± 8.94 | −72.97 ± 9.38 | −73.23 ± 9.61 | NS |
| FAI Score LAD, mean ± SD | 10.39 ± 7.01 | 9.12 ± 6.20 | 11.87 ± 8.23 | 0.05 |
| FAI Score LCX, mean ± SD | 11.24 ± 6.28 | 10.77 ± 6.13 | 13.02 ± 6.76 | 0.05 |
| FAI Score RCA, mean ± SD | 15.10 ± 11.94 | 14.74 ± 12.24 | 15.88 ± 10.36 | NS |
| FAI Score LCA, mean ±SD | 11.02 ± 6.48 | 9.78 ± 5.95 | 12.11 ± 7.21 | 0.005 |
| FAI Score TOTAL, mean ± SD | 11.90 ± 7.93 | 10.55 ± 7.32 | 13.01 ± 8.16 | 0.001 |
Baseline characteristics, comorbidities, and risk factors in the study population
| Parameters | Whole study sample (n =172) | Group 1 (COVID-19) (n = 80) | Group 2 (non-COVID-19) (n = 92) | P-value * |
|---|---|---|---|---|
| Male gender, n (%) | 115 (66.86%) | 49 (61.25%) | 66 (71.73%) | NS |
| Age at time of scan, mean ± SD | 62.43 ± 11.62 | 60.19 ± 10.10 | 62.84 ± 9.90 | NS |
| Smoking, n (%) | 31 (18.02%) | 10 (12.50%) | 21 (22.82%) | NS |
| Hypertension, n (%) | 146 (84.88%) | 65 (81.25%) | 82 (89.13%) | NS |
| Hypercholesterolemia, n (%) | 86 (50.00%) | 32 (40.00%) | 54 (58.69%) | 0.02 |
| Diabetes, n (%) | 47 (27.32%) | 19 (23.75%) | 28 (30.43%) | NS |
| Obesity, n (%) | 44 (25.58%) | 26 (32.50%) | 19 (20.65%) | 0.06 |
| BMI, mean ± SD | 27.57 ± 4.29 | 28.51 ± 4.21 | 26.93 ± 4.25 | 0.03 |
| PCI after CCTA, n (%) | 75 (43.60%) | 30 (37.50%) | 47 (51.08%) | NS |
| Multi-vessel PCI, n (%) | 25 (14.53%) | 8 (26.66%) | 18 (38.29%) | NS |
| Heart failure, n (%) | 127 (72.67%) | 61 (76.25%) | 70 (76.08%) | NS |
| LVEF (%), mean ± SD | 47.69 ± 5.07 | 48.34 ± 4.18 | 47.12 ± 5.71 | NS |
| Creatinine (mg/dl), mean ± SD | 0.97 ± 0.26 | 0.93 ± 0.23 | 1.00 ± 0.27 | NS |
| Total cholesterol (mg/dl), mean ± SD | 167.3 ± 47.13 | 161.4 ± 43.55 | 171.0 ± 49.24 | 0.07 |
| Triglycerides (mg/dl), mean ± SD | 145.7 ± 69.49 | 134.1 ± 75.04 | 154.0 ± 64.58 | 0.03 |
| COVID-19 vaccine, n (%) | 107 (62.20%) | 46 (57.50%) | 56 (60.86%) | NS |
| Time from COVID-19 to CCTA (days), mean ± SD | 134.2 ± 104.9 | |||
CaRI Heart® Coronary Inflammation
| Parameters | Whole study sample (n = 158) | Group 1 (COVID-19) (n = 75) | Group 2 (non-COVID-19) (n = 83) | P-value * |
|---|---|---|---|---|
| CaRi Heart® Risk, mean ± SD | 18.34 ± 16.02 | 11.34 ± 8.47 | 23.81 ± 18.31 | < 0.0001 |
| Duke Score, mean ± SD | 2.97 ± 1.36 | 2.54 ± 1.33 | 3.37 ± 1.27 | < 0.0001 |